Publications & Presentations

Below is a listing of scientific publications and presentations related to Idenix hepatitis C drug candidates.

IDX184, HCV nucleotide polymerase inhibitor

 McCarville et al, EASL 2011, 4.2.11
"No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects"

 IDX184 Phase 1 AAC Paper 2011
"Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects"

 Lalezari et al, AASLD 2010, 10.31.10
"A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naïve Genotype 1 HCV-Infected Subjects"

 McCarville et al; 6.25.10
"In Vitro and In Vivo Resistance Profile of IDX184, a Novel Nucleotide Analog for the Treatment of HCV Infection"
5th International Workshop on Hepatitis C-Resistance and New Compounds - June 24-25, 2010

 Lalezari et al, EASL 2010, 4.15.10
"Antiviral Activity, Pharmacokinetics and Safety of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naive HCV Genotype 1-infected Subjects”

 Lalezari et al, AASLD 2009, 11.2.09
"Antiviral Activity, Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide HCV Polymerase Inhibitor, in Patients with Chronic Hepatitis C”

 Lallos et al, AASLD 2009, 11.3.09
"Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, with Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon in vitro”

 Standring et al, EASL 2009, 4.24.09
“Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-Infected Chimpanzees”

 Zhou et al, EASL 2009, 4.25.09
“IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study”

 

IDX320, HCV protease inhibitor

 Reesink et al, AASLD 2010, 11.1.10
"Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C"

 Lallos et al; 6.25.10
"In Vitro Resistance and Cross-resistance Profiles of IDX320, a Potent Macrocyclic HCV Protease Inhibitor”
5th International Workshop on Hepatitis C-Resistance and New Compounds - June 24-25, 2010

 J. v.d. Wetering de Rooij et al; 6.23.10
"IDX320, A Novel Macrocyclic HCV Protease Inhibitor: Safety, Tolerability and Pharmacokinetics (PK) in a Phase I Clinical Study”
5th International Workshop on Clinical Pharmacology of Hepatitis Therapy - June 23-24, 2010

 Good et al, EASL 2010, 4.16.10
"Pharmacokinetic and Safety Profile of IDX320, a Novel and Potent HCV Protease Inhibitor”

 Lallos et al, EASL 2010, 4.16.10
"In Vitro Antiviral Activity of IDX320, a Novel and Potent Macrocyclic HCV Protease Inhibitor”

 

IDX375, HCV non-nucleoside polymerase inhibitor

 Bruijne et al, AASLD 2010, 11.2.10
"Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor"

 J. v.d. Wetering de Rooij et al; 6.23.10
"IDX375, A Novel Non-nucleoside HCV Polymerase Inhibitor: Safety, Tolerability and Pharmacokinetics (PK) in a Phase I Study"
5th International Workshop on Clinical Pharmacology of Hepatitis Therapy - June 23-24, 2010

 Good et al, EASL 2009, 4.23.09
“Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor”

 Bilello et al, AASLD 2008, 10.31.08
"In VitroActivity and Pharmacologic Properties of IDX375, a novel HCV non-nucleoside inhibitor”

 

NS5A Program

 McCarville et al, EASL 2011, 4.1.11
"Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypic in vitro antiviral activity"

 

HCV Combination Therapy

 Douglas Mayers, Victor De Gruttola 4.30.10
"Challenges in Designing Trials for Direct Acting Antiviral (DAA) Combination Therapy of HCV Infection”
FDA Public Hearing - April 30, 2010

 La Colla et al, EASL 2010, 4.16.10
"Triple Combinations of Direct-Acting Antiviral Agents Demonstrate Robust Anti-HCV Activity In Vitro”